IntegriChain delivers the life science industry’s largest and only data and business process platform for therapy commercialization and access. Manufacturers rely on our analytics, applications, managed services and expert advisors to power their operations and harness the value of their channel, patient and payer data.
View all products
From the first launch to ongoing market access execution, IntegriChain solves some of the most complex and pressing challenges associated with drug commercialization. We are the data and application backbone for market access departments of Life Sciences manufacturers, enabling them to accelerate their commercialization process, digitalize their operations, and get therapies to patients faster.
Solutions overview
To ensure you get the most out of your access and commercialization investment, IntegriChain provides a complete set of professional Advisory and Systems Integration Services designed to further your business and success.
Services overview
IntegriChain provides wide array of resources to help you navigate your journey to market access success.
Resources overview
We help all stakeholders in the life sciences industry drive access. We do this through our relentless focus on unifying all of the critical business functions for therapy commercialization and access – contracts and pricing, gross-to-net, channel, and patient services – unlocking strategic payer, provider, pharmacy and patient access insights for our life sciences customers.
Learn more about our company
Keep in touch with IntegrChain through our news and frequent events.
View all news & events
October 21, 2020 | 10:00 am ET
Siloed channel and market access data — combined with disconnected master data across the commercial systems landscape — creates a number of obstacles to a successful product launch and proactive engagement for both buy-and-bill and “specialty light” products. In this session, we’ll examine how Immunomedics implemented commercial analytics to support TrodelvyTM including territory performance reporting, incentive compensation, and enhanced targeting. We’ll also examine how to utilize unblinded 867 data as a foundational asset, and integrate it with the Veeva commercial data warehouse and CRM solution to improve visibility and value.
Please join Joshua Halpern, Co-Founder and EVP, Product and Strategy and Ushank Agarwal, Senior Director, Commercial Analytics, Immunomedics.
Watch now!
